USP Sounds Alarm As Delta-8 THC Noise Grows Louder In US Hemp Ingredients Market
Executive Summary
On same day USP published report on delta-8 THC, former FDA executive who led a marijuana policy working group while there advised that banishing the ingredient won’t come any easier than controlling the use of hemp ingredients in non-drug products subject to the agency’s regulatory oversight.
You may also be interested in...
CBD Will Be US FDA’s ‘One’ Lawful Hemp Compound, House Appropriators Anticipate
Reference in report accompanying House Appropriation Committee bill for FDA FY2023 budget isn’t binding and wasn’t appropriators’ first mention of agency’s response to de-scheduling hemp as a controlled substance. But their ’ statement was more pointed than in previous appropriation reports.
First US Warnings On Drug Claims By Delta-8 THC Supplements Also Describe Safety Concerns
Announcement and warnings, in addition to noting firms’ violative drug and disease claims, explain differences between delta-8 THC and other hemp-derived cannabinoids intended for de-scheduling as controlled substances in 2018 farm bill.
Emerging US Cannabinoid Market Sales Driver Could Drive Lawful Use Legislation Off The Rails
Delta-8 THC is a close chemical cousin to the substance recognized for intoxicating effects. Its effects aren't a settled question, along with whether it meets definition of hemp stated in 2018 farm bill.